Michael Klichinsky
Overview
Explore the profile of Michael Klichinsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
2328
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reiss K, Angelos M, Dees E, Yuan Y, Ueno N, Pohlmann P, et al.
Nat Med
. 2025 Feb;
PMID: 39920391
Chimeric antigen receptor (CAR) macrophages (CAR-Ms) mediate antitumor immunity via phagocytosis, cytokine release, activation of the tumor microenvironment and antigen presentation. We report results from a non-prespecified interim analysis of...
2.
Pierini S, Gabbasov R, Oliveira-Nunes M, Qureshi R, Worth A, Huang S, et al.
Nat Commun
. 2025 Jan;
16(1):706.
PMID: 39814734
We previously developed human CAR macrophages (CAR-M) and demonstrated redirection of macrophage anti-tumor function leading to tumor control in immunodeficient xenograft models. Here, we develop clinically relevant fully immunocompetent syngeneic...
3.
Smole A, Benton A, Poussin M, Eiva M, Mezzanotte C, Camisa B, et al.
Cancer Cell
. 2022 Dec;
40(12):1470-1487.e7.
PMID: 36513049
Despite the success of CAR-T cell cancer immunotherapy, challenges in efficacy and safety remain. Investigators have begun to enhance CAR-T cells with the expression of accessory molecules to address these...
4.
Sloas C, Gill S, Klichinsky M
Front Immunol
. 2021 Dec;
12:783305.
PMID: 34899748
Cellular immunotherapies represent a promising approach for the treatment of cancer. Engineered adoptive cell therapies redirect and augment a leukocyte's inherent ability to mount an immune response by introducing novel...
5.
Anderson N, Minutolo N, Gill S, Klichinsky M
Cancer Res
. 2020 Nov;
81(5):1201-1208.
PMID: 33203697
Adoptive cell therapy with genetically modified T cells has generated exciting outcomes in hematologic malignancies, but its application to solid tumors has proven challenging. This gap has spurred the investigation...
6.
Klichinsky M, Ruella M, Shestova O, Lu X, Best A, Zeeman M, et al.
Nat Biotechnol
. 2020 May;
38(8):947-953.
PMID: 32361713
Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic malignancies, but its application to solid tumors has been challenging. Given the unique effector functions of macrophages and...
7.
Ruella M, Xu J, Barrett D, Fraietta J, Reich T, Ambrose D, et al.
Nat Med
. 2018 Oct;
24(10):1499-1503.
PMID: 30275568
We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19 leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was unintentionally introduced into...
8.
Kim M, Yu K, Kenderian S, Ruella M, Chen S, Shin T, et al.
Cell
. 2018 Jun;
173(6):1439-1453.e19.
PMID: 29856956
The absence of cancer-restricted surface markers is a major impediment to antigen-specific immunotherapy using chimeric antigen receptor (CAR) T cells. For example, targeting the canonical myeloid marker CD33 in acute...
9.
Ruella M, Klichinsky M, Kenderian S, Shestova O, Ziober A, Kraft D, et al.
Cancer Discov
. 2017 Jun;
7(10):1154-1167.
PMID: 28576927
Patients with otherwise treatment-resistant Hodgkin lymphoma could benefit from chimeric antigen receptor T-cell (CART) therapy. However, Hodgkin lymphoma lacks CD19 and contains a highly immunosuppressive tumor microenvironment (TME). We hypothesized...
10.
Ruella M, Barrett D, Kenderian S, Shestova O, Hofmann T, Perazzelli J, et al.
J Clin Invest
. 2016 Aug;
126(10):3814-3826.
PMID: 27571406
Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative...